Oncogenes

Toronto Innovation Acceleration Partners (TIAP) adds novel KRAS oncology project to its LAB150 portfolio

Retrieved on: 
Thursday, December 12, 2019
Branches of biology, Biology, KRAS, Biochemistry, Signal transduction, Biotechnology, Biochemistry methods, Proteomics, Oncogenes, Protein–protein interaction, Ras GTPase, KRAS

Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member.

Key Points: 
  • Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member.
  • This latest LAB150 project aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners.
  • Recent therapeutic approaches are directed at the KRAS G12C mutation, but other common mutations, such as G12D and G12V, remain largely untargeted.
  • The innovative approach undertaken by the Stagljar lab differs from current modifying approaches by targeting specific proteinprotein interactions (PPIs) of KRAS and its downstream effectors.

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

Retrieved on: 
Thursday, November 21, 2019
Branches of biology, RTT, Bcl-2, Oncogenes, Programmed cell death, Chronic lymphocytic leukemia, Lymphoma, PI3K/AKT/mTOR pathway, Phosphoinositide 3-kinase inhibitor

An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.

Key Points: 
  • An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
  • BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers.
  • Preclinical studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target, and its benign safety profile should enable BP1002 combination therapy with approved agents.
  • This IND clearance for BP1002 marks an important regulatory milestone for Bio-Path, as we progress our second drug candidate into the clinic.

Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting

Retrieved on: 
Thursday, November 14, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, RTT, Cancer, Neoplasms, Sarcoma, Clinical medicine, Ewing's sarcoma, FUS, Oncogenes, Takeda Pharmaceutical Company, ERG, TK216, the Study, Oncternal Therapeutics

Study TK216-01, Oncternals ongoing Phase 1 study of TK216 in patients with relapsed or refractory Ewing sarcoma, is a first-in-human, multicenter clinical trial.

Key Points: 
  • Study TK216-01, Oncternals ongoing Phase 1 study of TK216 in patients with relapsed or refractory Ewing sarcoma, is a first-in-human, multicenter clinical trial.
  • Patients entering the trial had previously been treated with a median of four, and up to nine prior lines of systemic therapy.
  • TK216 has been generally well tolerated in this trial, with common side effects including myelosuppression, fatigue, nausea and alopecia.
  • Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma.

New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function

Retrieved on: 
Saturday, November 9, 2019
Branches of biology, Medicine, Clinical research, Clinical medicine, Epidermal growth factor receptor, Oncogenes, Placebo, Epidermal growth factor, Albuminuria

This analysis showed that INVOKANA provides a strong, consistent safety profile and efficacy at all tested eGFR levels.

Key Points: 
  • This analysis showed that INVOKANA provides a strong, consistent safety profile and efficacy at all tested eGFR levels.
  • In this prespecified secondary analysis, CREDENCE researchers investigated whether the effects of INVOKANA on clinically important outcomes were consistent across screening eGFR levels.
  • INVOKANA reduced A1c, blood pressure, body weight, and albuminuria (protein in the urine) compared to placebo across all eGFR subgroups.
  • Researchers also examined patients who ended the study with an eGFR below 30 mL/min/1.73 m2 (N=929; INVOKANA, 417; placebo, 512).

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

Retrieved on: 
Friday, November 8, 2019
Branches of biology, Programmed cell death, Apoptosis, Bcl-2, Oncogenes, Lymphoma

ET to report financial results for the third quarter ended September 30, 2019 and to provide a business overview.

Key Points: 
  • ET to report financial results for the third quarter ended September 30, 2019 and to provide a business overview.
  • A live audio webcast of the call will also be available on the Presentations section of the Companys website, www.biopathholdings.com .
  • An archived webcast will be available on the Bio-Path website approximately two hours after the event.
  • The Company is also developing BP1002, which targets the Bcl-2 protein and is expected to be evaluated for the treatment of lymphoma and solid tumors.

Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Cancer, RTT, Treatment of cancer, Clinical medicine, Medicine, Leukemia, Oncogenes, Immune system

We are pleased that AUTO1 data will be presented in three oral presentations at ASH.

Key Points: 
  • We are pleased that AUTO1 data will be presented in three oral presentations at ASH.
  • We are also looking forward to presenting data on our other hematological clinical programs at ASH.
  • AUTO2 is designed to address a key escape route used by hematological cancers in response to T cell therapies.
  • Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.

Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Global Pipeline Insight Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Pharmaceutical, Health, Tyrosine kinase receptors, Branches of biology, Oncogenes, Cell biology, Epidermal growth factor receptor, ErbB, ERBB4, ERBB3, Receptor tyrosine kinase

The "Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Retrieved on: 
Tuesday, October 29, 2019
Branches of biology, Cancer, Proteins, Tumor suppressor genes, Oncology, Antineoplastic drugs, Mdm2, Oncogenes, P53, Chemotherapy

Our nonclinical results show that ALRN-6924 significantly reduces the toxic effects of chemotherapy in normal, healthy bone marrow cells and gastrointestinal tissues, stated Allen Annis, Ailerons SVP of Research.

Key Points: 
  • Our nonclinical results show that ALRN-6924 significantly reduces the toxic effects of chemotherapy in normal, healthy bone marrow cells and gastrointestinal tissues, stated Allen Annis, Ailerons SVP of Research.
  • Our findings suggest that prophylactic use of ALRN-6924 can protect p53-wildtype normal cells while allowing chemotherapy to be effective against p53 mutant cancer cells.
  • With this mechanism, we believe ALRN-6924 may enable a precision-medicine strategy to prevent chemotherapy-related toxicities in patients with p53-mutated cancer.
  • Poster Title: The Investigational Peptide Drug ALRN-6924, a Dual Inhibitor of MDMX and MDM2, is an Effective Myelopreservation Agent.

Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

Retrieved on: 
Tuesday, October 22, 2019
Enzymes, Tyrosine kinases, Branches of biology, CD135, Bruton's tyrosine kinase, Protein kinase inhibitor, Tumors of the hematopoietic and lymphoid tissues, Oncogenes, Tyrosine kinase inhibitors, ETV6

The live conference call can also be accessed through a link on the Investor Relations section of Aptoses website at ir.aptose.com .

Key Points: 
  • The live conference call can also be accessed through a link on the Investor Relations section of Aptoses website at ir.aptose.com .
  • Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required.
  • An archived version of the webcast along with a transcript will be available on the companys website for 30 days.
  • CG-806, an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor being developed to treat AML and certain B cell malignancies, is in a Phase 1 clinical trial for hematologic malignancies.

KRAS Inhibitors Competitor Analysis, 2019 Report - ResearchAndMarkets.com

Retrieved on: 
Friday, October 18, 2019
Pharmaceutical, Genetics, Health, Oncology, KRAS, Oncogenes, KRAS, Ras GTPase

The "Competitor Analysis: KRAS Inhibitors" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Competitor Analysis: KRAS Inhibitors" report has been added to ResearchAndMarkets.com's offering.
  • This Competitive Intelligence report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines targeting the Kirsten RAt Sarcoma virus oncogene (KRAS) for treatment of cancer as of October 2019.
  • Encouragingly, recent studies have aroused renewed interest in the development of KRAS inhibitors either directly towards mutant KRAS or against the crucial steps required for KRAS activation.
  • The report includes a compilation of currently active projects in research and development of KRAS inhibitors for the treatment of cancer.